Sami-Sabinsa Group, the multi-national health science company founded by the late Dr. Muhammed Majeed 36 years ago, announces Dr. Anju Majeed as Sami-Sabinsa Group Executive Chairperson, assuming the role her father held until his death on March 13, 2024. The company also announced Shaheen Majeed as Global Managing Director & CEO.

Sami-Sabinsa Group is delighted to announce the elevation of Dr. Anju Majeed to the role of Group Executive Chairperson of Sami-Sabinsa Group Limited.

anju-majeed

Anju Majeed PhD, received Bachelor’s and Master’s degrees from Rutgers University in microbiology and molecular genetics, a further Master’s in biological sciences from Johns Hopkins, and her PhD. in Microbiology from Bharathidasan University. She was a National Institute of Health Research Fellow from 2001 – 2005. She has expertise in SAS and clinical SAS database management. Anju is based in the Sami-Sabinsa Group headquarters in Bengaluru, India.

A highly motivated person, she drives new technologies and processes, develops new product formulations, and creates scalable manufacturing processes for Sami, which are further used in clinical trials through all phases of development. As Sami-Sabinsa Group Director and Senior Scientist, she worked closely with analytical and formulation scientists and operates via multi-functional, global teams, including API manufacturing, process R&D, pre-formulation, and pilot plant operations. The passion that drives her comes from perseverance and a strong desire to contribute to the society.

Mr. Shaheen Majeed has been inducted onto the Board of Directors of the Sami-Sabinsa Group effective April 01, 2024 and will be heading the Sami-Sabinsa Group as Global Managing Director & Chief Executive Officer.

anju-majeed

For 25 years, Shaheen was instrumental in building Sabinsa into a global leader with a vast ingredient portfolio. He held various positions of increasing responsibilities with Sabinsa, including roles in sales, supply chain, manufacturing, and global marketing, culminating in four years as President Worldwide. He was instrumental in executing the global strategies, expanding the company’s footprints, ensuring cGMP and regulatory compliance, guiding several clinical studies through the publishing process, and he currently holds 46 US & International patents. He previously served as CEO of three subsidiaries of BGG World: HB Natural Ingredients, BGG Americas, and Algae Health Sciences.

The entire family of the Sami-Sabinsa Group is delighted to welcome Dr. Anju Majeed and Mr. Shaheen Majeed to their new roles, which will provide the Group with the opportunity for further growth and to advance Dr. Muhammed Majeed’s legacy.

top